Rapid screening for entry inhibitors of highly pathogenic viruses under low-level biocontainment

PLoS ONE

Volumn 7, Issue 3, 2012, Pages

  Talekar, Aparna ^a   Pessi, Antonello ^b   Glickman, Fraser ^c   Sengupta, Uttara ^a   Briese, Thomas ^d   Whitt, Michael A ^e   Mathieu, Cyrille ^f   Horvat, Branka ^f,g   Moscona, Anne ^a   Porotto, Matteo ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b PeptiPharma   (Italy)

^c ROCKEFELLER UNIVERSITY   (United States)

^d Columbia University ^*  (United States)

^e UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^f UNIVERSITÉ DE LYON   (France)

^g UNIVERSITÉ LYON 1   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; COMPLEMENTARY DNA; DNA VACCINE; HENDRA F POLYCLONAL ANTIBODY; HENDRA G POLYCLONAL ANTIBODY; NIPAH F MONOCLONAL ANTIBODY; NIPAH G MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG; VIRUS ANTIBODY; NEUTRALIZING ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOASSAY; BIOSAFETY; CONTROLLED STUDY; DRUG DETERMINATION; DRUG SCREENING; DRUG SYNTHESIS; GENETIC TRANSFECTION; HENDRA VIRUS; HENIPAVIRUS; HUMAN; HUMAN CELL; IMMUNIZATION; MODIFIED MULTICYCLE PSEUDOTYPED VIRAL REPLICATION ASSAY; NIPAH VIRUS; NONHUMAN; RABBIT; RAT; VALIDATION PROCESS; VIRUS NEUTRALIZATION; ANIMAL; BIOLOGY; CELL STRAIN HEK293; CERCOPITHECUS; CHEMISTRY; IMMUNOTHERAPY; METABOLISM; METHODOLOGY; PHARMACEUTICS; VERO CELL; VIRUS REPLICATION;

HENIPAVIRUS; JUNIN VIRUS; NIPAH VIRUS; RATTUS;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIVIRAL AGENTS; CERCOPITHECUS AETHIOPS; COMPUTATIONAL BIOLOGY; DNA, COMPLEMENTARY; DRUG EVALUATION, PRECLINICAL; HEK293 CELLS; HENDRA VIRUS; HUMANS; IMMUNOTHERAPY; NIPAH VIRUS; RATS; TECHNOLOGY, PHARMACEUTICAL; VERO CELLS; VIRUS REPLICATION;

EID: 84857707719     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0030538     Document Type: Article

References (40)

1. Wong KT, (2010) Emerging epidemic viral encephalitides with a special focus on henipaviruses. Acta Neuropathol 120: 317-325.
2. Geisbert TW, Jahrling PB, (2004) Exotic emerging viral diseases: progress and challenges. Nat Med 10: S110-121.
3. Drosten C, Preiser W, GüNther S, Schmitz H, Doerr HW, (2003) Severe Acute Respiratory Syndrome: Identification of the Etiological Agent. Trends in Molecular Medicine 9: 325-327.
4. Garten RJ, Davis CT, Russell CA, Shu B, Lindstrom S, et al. (2009) Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans. Science 325: 197-201.
5. Chua KB, Goh KJ, Wong KT, Kamarulzaman A, Tan PS, et al. (1999) Fatal encephalitis due to Nipah virus among pig-farmers in Malaysia. Lancet 354: 1257-1259.
6. Murray K, Selleck P, Hooper P, Hyatt A, Gould A, et al. (1995) A morbillivirus that caused fatal disease in horses and humans. Science (Washington) 268: p94-97.
7. Rahman MA, Hossain MJ, Sultana S, Homaira N, Khan SU, et al. (2011) Date Palm Sap Linked to Nipah Virus Outbreak in Bangladesh, 2008. Vector Borne Zoonotic Dis.
8. Gurley ES, Montgomery JM, Hossain MJ, Bell M, Azad AK, et al. (2007) Person-to-person transmission of Nipah virus in a Bangladeshi community. Emerg Infect Dis 13: 1031-1037.
9. Homaira N, Rahman M, Hossain MJ, Epstein JH, Sultana R, et al. (2010) Nipah virus outbreak with person-to-person transmission in a district of Bangladesh, 2007. Epidemiol Infect 138: 1630-1636.
10. Luby SP, Gurley ES, Hossain MJ, (2009) Transmission of human infection with Nipah virus. Clin Infect Dis 49: 1743-1748.
11. Hossain MJ, Gurley ES, Montgomery JM, Bell M, Carroll DS, et al. (2008) Clinical presentation of nipah virus infection in Bangladesh. Clin Infect Dis 46: 977-984.
12. Sejvar JJ, Hossain J, Saha SK, Gurley ES, Banu S, et al. (2007) Long-term neurological and functional outcome in Nipah virus infection. Ann Neurol 62: 235-242.
13. Mungall BA, Middleton D, Crameri G, Bingham J, Halpin K, et al. (2006) Feline model of acute nipah virus infection and protection with a soluble glycoprotein-based subunit vaccine. J Virol 80: 12293-12302.
14. Guillaume V, Contamin H, Loth P, Georges-Courbot MC, Lefeuvre A, et al. (2004) Nipah virus: vaccination and passive protection studies in a hamster model. J Virol 78: 834-840.
15. Wang X, Ge J, Hu S, Wang Q, Wen Z, et al. (2006) Efficacy of DNA immunization with F and G protein genes of Nipah virus. Ann N Y Acad Sci 1081: 243-245.
16. Bossart KN, Zhu Z, Middleton D, Klippel J, Crameri G, et al. (2009) A neutralizing human monoclonal antibody protects against lethal disease in a new ferret model of acute nipah virus infection. PLoS Pathog 5: e1000642.
17. Guillaume V, Contamin H, Loth P, Grosjean I, Courbot MC, et al. (2006) Antibody prophylaxis and therapy against Nipah virus infection in hamsters. J Virol 80: 1972-1978.
18. Guillaume V, Wong KT, Looi RY, Georges-Courbot MC, Barrot L, et al. (2009) Acute Hendra virus infection: Analysis of the pathogenesis and passive antibody protection in the hamster model. Virology 387: 459-465.
19. Aljofan M, Porotto M, Moscona A, Mungall BA, (2008) Development and validation of a chemiluminescent immunodetection assay amenable to high throughput screening of antiviral drugs for Nipah and Hendra virus. J Virol Methods 149: 12-19.
20. Porotto M, Orefice G, Yokoyama CC, Mungall BA, Realubit R, et al. (2009) Simulating henipavirus multicycle replication in a screening assay leads to identification of a promising candidate for therapy. J Virol 83: 5148-5155.
21. Briese T, Paweska JT, McMullan LK, Hutchison SK, Street C, et al. (2009) Genetic detection and characterization of Lujo virus, a new hemorrhagic fever-associated arenavirus from southern Africa. PLoS Pathog 5: e1000455.
22. Larson RA, Dai D, Hosack VT, Tan Y, Bolken TC, et al. (2008) Identification of a broad-spectrum arenavirus entry inhibitor. J Virol 82: 10768-10775.
23. Yonezawa A, Cavrois M, Greene WC, (2005) Studies of ebola virus glycoprotein-mediated entry and fusion by using pseudotyped human immunodeficiency virus type 1 virions: involvement of cytoskeletal proteins and enhancement by tumor necrosis factor alpha. J Virol 79: 918-926.
24. Negrete OA, Chu D, Aguilar HC, Lee B, (2007) Single Amino Acid Changes in the Nipah and Hendra Virus Attachment Glycoproteins Distinguish EphrinB2 from EphrinB3 Usage. J Virol 81: 10804-10814.
25. Falzarano D, Geisbert TW, Feldmann H, (2011) Progress in filovirus vaccine development: evaluating the potential for clinical use. Expert review of vaccines 10: 63-77.
26. Geisbert TW, Feldmann H, (2011) Recombinant vesicular stomatitis virus-based vaccines against Ebola and Marburg virus infections. The Journal of infectious diseases 204 (Suppl 3): S1075-1081.
27. Marzi A, Ebihara H, Callison J, Groseth A, Williams KJ, et al. (2011) Vesicular stomatitis virus-based Ebola vaccines with improved cross-protective efficacy. The Journal of infectious diseases 204 (Suppl 3): S1066-1074.
28. Talekar A, Pessi A, Porotto M, (2011) Infection of primary neurons mediated by nipah virus envelope proteins: role of host target cells in antiviral action. J Virol 85: 8422-8426.
29. Porotto M, Rockx B, Yokoyama C, Talekar A, DeVito I, et al. (2010) Inhibition of Nipah Virus Infection In Vivo: Targeting an Early Stage of Paramyxovirus Fusion Activation during Viral Entry. PLoS Pathog 6 (10): e1001168 doi:10.1371/journal.ppat.1001168.
30. Porotto M, Orefice G, Yokoyama C, Mungall B, Realubit R, et al. (2009) Simulating henipavirus multicycle replication in a screening assay leads to identification of a promising candidate for therapy. J Virol 83: 5148-5155.
31. Lagerqvist N, Naslund J, Lundkvist A, Bouloy M, Ahlm C, et al. (2009) Characterisation of immune responses and protective efficacy in mice after immunisation with Rift Valley Fever virus cDNA constructs. Virol J 6: 6.
32. Zheng L, Wang F, Yang Z, Chen J, Chang H, et al. (2009) A single immunization with HA DNA vaccine by electroporation induces early protection against H5N1 avian influenza virus challenge in mice. BMC Infect Dis 9: 17.
33. Chen H, Wen B, Deng Y, Wang W, Yin X, et al. (2011) The enhanced effect of DNA immunization combined in vivo electroporation of hepatitis B Virus Core-PreS1 and S-PreS1 plasmids. Clin Vaccine Immunol.
34. Luby SP, Hossain MJ, Gurley ES, Ahmed BN, Banu S, et al. (2009) Recurrent zoonotic transmission of Nipah virus into humans, Bangladesh, 2001-2007. Emerg Infect Dis 15: 1229-1235.
35. Zhu Z, Dimitrov AS, Bossart KN, Crameri G, Bishop KA, et al. (2006) Potent neutralization of Hendra and Nipah viruses by human monoclonal antibodies. J Virol 80: 891-899.
36. Whitt MA, (2010) Generation of VSV pseudotypes using recombinant DeltaG-VSV for studies on virus entry, identification of entry inhibitors, and immune responses to vaccines. J Virol Methods 169: 365-374.
37. Kirschner M, Monrose V, Paluch M, Techodamrongsin N, Rethwilm A, et al. (2006) The production of cleaved, trimeric human immunodeficiency virus type 1 (HIV-1) envelope glycoprotein vaccine antigens and infectious pseudoviruses using linear polyethylenimine as a transfection reagent. Protein Expr Purif 48: 61-68.
38. Porotto M, Yokoyama CC, Palermo LM, Mungall B, Aljofan M, et al. (2010) Viral entry inhibitors targeted to the membrane site of action. J Virol 84: 6760-6768.
39. Guillaume V, Lefeuvre A, Faure C, Marianneau P, Buckland R, et al. (2004) Specific detection of Nipah virus using real-time RT-PCR (TaqMan). J Virol Methods 120: 229-237.
40. Zhang JH, Chung TD, Oldenburg KR, (1999) A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays. J Biomol Screen 4: 67-73.